What Triggered Ardelyx's Post-Earnings Plunge
Ardelyx (ARDX) shares plunged 14.99% after its Q4 and full-year 2025 earnings report. The decline was primarily driven by a Q4 EPS miss and a perceived slowdown in IBSRELA's 2026 growth guidance, despite strong 2025 revenue performance for the drug. Additionally, a significant decrease in XPHOZAH revenue and rising operating expenses contributed to investor disappointment, leading to a "sell the news" event.
ARDX (NASDAQ: ARDX) reports 5,355 RSUs vest; insider sales noted
A recent SEC Form 144 filing for Ardelyx (NASDAQ: ARDX) indicates that 5,355 restricted stock units (RSUs) vested on May 19, 2026, and are listed as securities to be sold. The filing also detailed prior sales on February 20, 2026, totaling 2,033 shares for approximately $11,886. The report is considered routine, reflecting individual holder transactions rather than a corporate finance action.
Ardelyx president & CEO Michael Raab sells $261,612 of ARDX stock
Ardelyx President & CEO Michael Raab sold 41,666 shares of ARDX stock valued at $261,612 on May 15, 2026, while also exercising options for 20,833 shares. These transactions were executed under a pre-arranged 10b5-1 trading plan. Despite recent Q1 2026 earnings missing analyst expectations, the company showed strong year-over-year growth and presented positive long-term data for its drug XPHOZAH.
Ardelyx president & CEO Michael Raab sells $261,612 of ARDX stock
Michael Raab, President & CEO of Ardelyx, Inc. (NASDAQ: ARDX), sold 41,666 shares of company stock for $261,612 and exercised options on 20,833 shares on May 15, 2026. These transactions were executed under a pre-arranged 10b5-1 trading plan. Despite recent Q1 2026 earnings missing analyst expectations, Ardelyx showed strong year-over-year growth and presented positive long-term data for its drug XPHOZAH.
ARDX (NASDAQ: ARDX) files Form 144 for 24,986 RSUs vesting
Ardelyx (NASDAQ: ARDX) has filed a Form 144 related to the vesting of 24,986 restricted stock units (RSUs) on May 19, 2026. The filing also details three dispositions made by Mike Kelliher on February 20, 2026, totaling 9,595 shares with reported proceeds of $49,465.41, $6,622.29, and $11.41 respectively. This notice is considered a routine procedural filing concerning employee stock ownership and recent insider sales.
Ardelyx Insider Sold Shares Worth $261,612, According to a Recent SEC Filing
An insider at Ardelyx recently sold shares valued at $261,612. This transaction was disclosed in a recent SEC filing, indicating a significant insider sale at the company.
Ardelyx Insider Sold Shares Worth $261,612, According to a Recent SEC Filing
An insider at Ardelyx, Inc. (NASDAQ: ARDX) sold shares valued at $261,612, as disclosed in a recent SEC filing. The company, a commercial-stage biopharmaceutical firm, focuses on developing and commercializing innovative medicines, including IBSRELA and XPHOZAH. Ardelyx is currently trading at $6.265 USD, with analysts having a "BUY" consensus and an average target price of $16.33 USD.
ARDX (NASDAQ: ARDX) files Form 144 for 7,771 vested RSUs and lists recent insider sales
Ardelyx (NASDAQ: ARDX) has filed a Form 144, indicating an intended transfer of 7,771 shares of Common Stock related to the vesting of restricted stock units on May 19, 2026, for services rendered. The filing also details recent dispositions by John E. Bishop on February 20, 2026, totaling 3,179 shares with reported aggregate proceeds. This compensation-driven issuance signals equity awards becoming fully owned by an employee.
Insider sale reported for ARDX (ARDX): 24,041 RSU shares vest
An insider trading filing (Form 144) for Ardelyx (ARDX) on May 19, 2026, disclosed the vesting of 24,041 restricted stock units (RSU). The filing also reported previous open market sales by Laura A. Williams on February 20, 2026, totaling 7,192 shares for $42,181.08 and 984 shares for $5,622.38. These transactions involve common stock handled through Morgan Stanley Smith Barney LLC.
Ardelyx (ARDX) CEO sells 41,666 shares in 10b5-1 trade, exercises options
Ardelyx (ARDX) President & CEO Michael Raab sold 41,666 shares of common stock at a weighted average price of $6.2788 under a pre-arranged 10b5-1 trading plan and exercised 20,833 stock options at $0.99 per share on May 15, 2026. After these transactions, Raab directly holds 1,814,447 common shares and 332,501 stock options, along with indirect holdings through family trusts. This insider activity is described as routine liquidity and compensation management and is considered neutral for investors.
A Look At Ardelyx (ARDX) Valuation After New Long Term XPHOZAH Data Strengthens Safety And Efficacy Profile
Ardelyx (ARDX) is receiving renewed attention following the presentation of long-term data for its drug XPHOZAH, highlighting its safety and efficacy. Despite recent stock dips, the company exhibits strong annual revenue growth, and an analysis suggests Ardelyx is undervalued, with a fair value estimated at $16.33 per share, significantly higher than its current trading price. This positive outlook is driven by expanding addressable markets due to chronic kidney disease and gastrointestinal disorders, coupled with improvements in market access and sales force expansion.
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
Ardelyx Inc. (Nasdaq: ARDX), a biopharmaceutical company, announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026. The event is scheduled for June 3 at 9:55 a.m. ET in New York. A live webcast and subsequent replay will be available on the Ardelyx website.
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
Ardelyx, Inc. announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET. The commercial-stage biopharmaceutical company will provide a live webcast of the event on its investor relations website, with a replay available afterward. Ardelyx focuses on developing and commercializing innovative medicines, including two approved products, IBSRELA® and XPHOZAH®.
A Look At Ardelyx (ARDX) Valuation After New Long Term XPHOZAH Data Strengthens Safety And Efficacy Profile
Ardelyx (ARDX) recently presented new long-term data for its drug XPHOZAH, strengthening its safety and efficacy profile, especially relevant for chronic kidney disease and gastrointestinal disorders. Despite a recent dip in share price, the company has shown strong long-term performance and revenue growth. Simply Wall St values Ardelyx at $16.33 per share, significantly higher than its current $6.11, citing expanding market demand and improved market access as key growth drivers.
Ardelyx (ARDX) Is Down 8.1% After New Long-Term XPHOZAH Dialysis Data - Has The Bull Case Changed?
Ardelyx (ARDX) shares dropped 8.1% after new long-term data for its drug XPHOZAH in dialysis patients were released. While the data reinforced XPHOZAH's safety and efficacy in lowering serum phosphate, the article emphasizes that the key near-term risk remains Medicare and broader payer access, which heavily influences the drug's commercial success and Ardelyx's path to profitability. The company's 2026 revenue guidance for both XPHOZAH and IBSRELA remains a critical benchmark for investors to assess the impact of these new data.
Ardelyx (ARDX) Is Down 8.1% After New Long-Term XPHOZAH Dialysis Data - Has The Bull Case Changed?
Ardelyx (ARDX) recently released new long-term data for its drug XPHOZAH, showing sustainable phosphate reduction in dialysis patients without adverse effects on other markers. While this strengthens the drug's safety profile, the primary investment risk remains payer access and reimbursement, which will dictate XPHOZAH’s commercial success and Ardelyx's path to profitability. The company reaffirmed its 2026 revenue guidance for both XPHOZAH and IBSRELA, setting concrete expectations for investors.
Janus Henderson (ARDX) discloses 8.37M‑share, 3.4% position in Ardelyx
Janus Henderson Group plc has reported a beneficial ownership of 8,371,234 shares, representing 3.4% of Ardelyx (ARDX) common stock, as of March 31, 2026. This stake is held through multiple Janus Henderson asset-management entities, with shared voting and dispositive power. The filing clarifies that while the asset managers exercise control over the shares, the actual Managed Portfolios retain the rights to dividends and sale proceeds.
Ardelyx, Inc. $ARDX Stock Position Increased by Vanguard Group Inc.
Vanguard Group Inc. increased its stake in Ardelyx, Inc. (NASDAQ:ARDX) by 3.3% in the fourth quarter, purchasing an additional 610,162 shares and bringing its total holdings to over 18.9 million shares. Several other institutional investors also modified their positions. Despite Ardelyx reporting an EPS loss that missed estimates, analysts maintain a "Moderate Buy" rating with a consensus target price of $15.70.
State Street (ARDX) reports 13.6M-share | 5.5% stake via advisory entities
State Street Corporation has reported a beneficial ownership of 13,604,307 shares, or 5.5%, of Ardelyx, Inc. common stock through its advisory subsidiaries. The Schedule 13G filing indicates shared voting power for 12,897,628 shares and shared dispositive power for all 13,604,307 shares, signifying a passive investment rather than an intent to control. This disclosure provides transparency on the ownership landscape of Ardelyx shares, with the filing signed on May 12, 2026.
TradingKey
This page on TradingKey provides an overview of Ardelyx Inc (ARDX) stock, including its current trading price, market capitalization, and P/E ratio. It offers various sections like Financials, Discussions, and Analysis for investors, alongside tools and educational resources provided by TradingKey. The site explicitly states that it offers general investment information and not financial advice.
Assessing Ardelyx (ARDX) Valuation After New Long Term XPHOZAH Safety Data Presentation
Ardelyx (ARDX) presented new long-term safety data for XPHOZAH in dialysis patients with hyperphosphatemia, reinforcing its safety profile. Despite recent short-term easing in stock price, the company has a strong one-year return and analysts see significant undervaluation with a fair value target of $16.33, more than double its current trading price of $6.78. However, investors should consider risks like reliance on tenapanor-based products and Medicare reimbursement uncertainties.
Assessing Ardelyx (ARDX) Valuation After New Long Term XPHOZAH Safety Data Presentation
Ardelyx (ARDX) is attracting attention after presenting new long-term safety data for its drug XPHOZAH, reinforcing its profile for dialysis patients. Despite a strong 92.07% return over the past year, the stock has eased recently, making its current valuation of $6.78 against an analyst target of $16.33 a point of interest. The article suggests Ardelyx is 58.5% undervalued, but cautions investors to weigh key risks like reliance on tenapanor-based products and Medicare reimbursement uncertainty.
Why Ardelyx (ARDX) Is Up 10.3% After New Long-Term XPHOZAH Dialysis Data And What's Next
Ardelyx's stock rose 10.3% after presenting new long-term data for its drug XPHOZAH, showing its efficacy and safety in chronic kidney disease patients on dialysis. This data supports XPHOZAH's role as an add-on therapy for hyperphosphatemia but the company's investment narrative still largely depends on reimbursement and access, especially concerning Medicare and CMS decisions. While analysts project significant revenue growth, investor outlook hinges on how payers respond and whether the company can meet its 2026 revenue guidance of US$110 million to US$120 million for XPHOZAH.
Why Ardelyx (ARDX) Is Up 10.3% After New Long-Term XPHOZAH Dialysis Data And What's Next
Ardelyx (ARDX) shares rose 10.3% following the release of new long-term data for XPHOZAH at the National Kidney Foundation’s Spring Clinical Meetings. The data demonstrated that XPHOZAH safely and effectively reduced serum phosphate in dialysis patients without negatively impacting other health markers, strengthening its clinical position. While the data is positive, the company's investment narrative continues to depend on managing reimbursement and cost pressures, particularly concerning Medicare and CMS decisions, as Ardelyx reaffirms its 2026 revenue guidance for XPHOZAH.
Ardelyx presents long-term safety data for XPHOZAH at NKF meeting
Ardelyx Inc. presented long-term safety data for its drug XPHOZAH (tenapanor) at the National Kidney Foundation's Spring Clinical Meetings. The analysis of two open-label trials showed no clinically meaningful changes in most serum electrolytes or nutrition biomarkers, aside from the intended phosphate reduction. Despite a recent Q1 2026 earnings miss, the company's shares have surged by 92% over the past year, and analysts project profitability for the current year.
Ardelyx presents long-term safety data for XPHOZAH at NKF meeting
Ardelyx Inc. presented long-term safety data for its drug XPHOZAH at the National Kidney Foundation's Spring Clinical Meetings, showing no significant changes in serum electrolytes (other than phosphate reduction), nutrition, body mass, or blood pressure. This analysis, from the NORMALIZE and OPTIMIZE studies, supports XPHOZAH's use for chronic kidney disease patients on dialysis, despite the company recently reporting a first-quarter earnings miss. The company's stock has seen substantial growth over the past year, and analysts project profitability this year.
Dialysis drug cut phosphate without shifting other electrolytes in trials
Ardelyx presented a post hoc analysis of its drug XPHOZAH (tenapanor) at the NKF Spring Clinical Meetings, showing that long-term use in dialysis patients with hyperphosphatemia reduced serum phosphate without causing clinically meaningful changes in other serum electrolytes, nutrition, body mass, or blood pressure. The analysis utilized data from the 18-month NORMALIZE extension study and the 26-week OPTIMIZE study, reinforcing XPHOZAH's safety profile as an add-on therapy for patients inadequately controlled by phosphate binders.
Ardelyx, Inc. (NASDAQ:ARDX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Ardelyx, Inc. recently released its first-quarter results, prompting analysts to update their financial models. The company reported a significant increase in revenue and a reduction in net loss, beating analyst expectations. Despite a notable rise in its stock price over the past year, analysts have slightly decreased next year's EPS estimates, though they raised revenue forecasts.
ARDX SEC Filings - Ardelyx 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Ardelyx's SEC filings, including annual 10-K reports, quarterly 10-Q earnings, and 8-K material event forms, with AI-powered summaries. Recent filings highlight board member stock-based compensation, a significant director stock purchase, and outcomes of the 2025 Annual Meeting of Stockholders regarding director elections and equity plan amendments. The platform tracks 83 filings, with the most recent filed on June 24, 2025, offering insights into the biopharmaceutical company's financial condition, governance, and key corporate events.
Ardelyx, Inc. (NASDAQ:ARDX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Ardelyx, Inc. recently released its first-quarter results, leading analysts to update their financial estimates for the company. While revenue expectations remained largely unchanged, there was a noticeable increase in earnings per share (EPS) forecasts. Investors should consider these revised estimates as they evaluate the company's future performance.
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Ardelyx, Inc. (NASDAQ:ARDX) recently announced its first-quarter results, showing a 15% share surge but reporting a statutory loss of US$0.15 per share despite revenues exceeding expectations. Analysts have reconfirmed revenue estimates for 2026 at US$545.5m, reflecting a significant improvement, but have revised their earnings forecasts from a profit to a loss of US$0.046 per share. Despite the shift to projected losses, the consensus price target remains unchanged at US$16.33, indicating that the business performance is largely in line with expectations.
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Ardelyx, Inc. (NASDAQ:ARDX) recently announced its first-quarter results, showing a 15% surge in shares and revenues exceeding expectations. Despite the revenue beat, statutory earnings reported a loss, leading analysts to update their forecasts. While revenue estimates for 2026 remain largely unchanged, analysts now predict a loss instead of a profit, although their consensus price target for ARDX shows no major alteration.
A Look At Ardelyx (ARDX) Valuation After Strong Q1 Results And Updated 2026 Guidance
Ardelyx (ARDX) reported strong Q1 2026 results with increased revenue and updated 2026 guidance for IBSRELA and XPHOZAH. Despite a 66.59% share price increase over the last year, the stock is currently trading at US$6.88 against a fair value estimate of US$16.10, suggesting it is significantly undervalued. However, potential risks include reimbursement challenges with Medicare and substantial debt, which investors should consider alongside the positive outlook.
AIGH Capital Management LLC Purchases 951,500 Shares of Ardelyx, Inc. $ARDX
AIGH Capital Management LLC significantly increased its stake in Ardelyx, Inc. (NASDAQ: ARDX) by 479.3%, purchasing an additional 951,500 shares. This move makes Ardelyx its 19th largest holding, despite the company reporting a Q1 EPS miss and continued unprofitability, with insiders also selling shares. Q1 revenues, however, beat estimates, driven by strong IBSRELA growth, and the company confirmed full-year revenue guidance.
Ardelyx (ARDX) Is Up 6.2% After Revenue Rises And Loss Narrows As New CLO Joins
Ardelyx (ARDX) saw its revenue rise to US$94.47 million in Q1 2026, up from US$74.11 million a year prior, while its net loss narrowed to US$37.61 million. The company also appointed Felecia W. Ettenberg as its new Chief Legal Officer, a move that could enhance its operational and risk-management profile, especially considering its exposure to reimbursement and regulatory complexities with its IBSRELA and XPHOZAH therapies. Analysts project the company's revenue to reach $979.2 million and earnings to hit $302.8 million by 2029, with a fair value estimate of $16.10, indicating a significant upside.
Ardelyx (ARDX) Is Up 6.2% After Revenue Rises And Loss Narrows As New CLO Joins
Ardelyx (ARDX) shares rose 6.2% after the company reported increased revenue and a narrower net loss for Q1 2026. Revenue climbed to US$94.47 million, and the net loss decreased to US$37.61 million. The company also appointed Felecia W. Ettenberg as its new Chief Legal Officer, a strategic move given its exposure to reimbursement complexities related to its IBSRELA and XPHOZAH therapies.
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
Ardelyx, Inc. announced strong financial results for the first quarter of 2026, with total product revenue reaching $93.4 million, marking a 38% increase year-over-year. This growth was largely driven by a 58% increase in IBSRELA revenue to $70.1 million. The company reaffirmed its full-year 2026 revenue guidance for both IBSRELA and XPHOZAH and reported a strong cash position of $238.1 million, enabling continued investment in clinical trials and pipeline development.
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2026 Earnings Call Transcript
Ardelyx, Inc. discussed its Q1 2026 financial results, highlighting significant revenue growth for Ibsrela and Exposa, despite missing EPS expectations. The company reiterated its full-year 2026 revenue guidance for both products and detailed its strategy for pipeline expansion, including the EXCEL Phase 3 trial for Ibsrela in chronic idiopathic constipation and the development of a next-generation NHE3 inhibitor. Financial strength was emphasized, along with a focus on disciplined capital allocation to drive profitability and long-term growth.
ARDELYX, INC. 1Q 2026: Revenue $94.5M, EPS $(0.15) — 10-Q Summary
ARDELYX, INC. reported its first-quarter 2026 results, showing a revenue of $94.5 million, marking a 27% increase year-over-year, and a reduced net loss of $37.6 million compared to $41.1 million in Q1 2025. Diluted EPS improved to $(0.15) from $(0.17). The growth was primarily driven by a 38% rise in product sales, particularly a 58% increase in IBSRELA sales, and progress in pipeline development with the initiation of the ACCEL Phase 3 trial.
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
Ardelyx (ARDX) reported Q1 2026 revenue of $94.47 million, exceeding the Zacks Consensus Estimate by 3.24%, and an EPS of -$0.15. Key metrics show product sales, net, increased by 37.7% year-over-year, with IBSRELA sales up 57.8%. The company's stock has seen a -1.6% return over the past month, contrasting with the S&P 500's +12.2% change, and currently holds a Zacks Rank #3 (Hold).
ARDELYX ($ARDX) Releases Q1 2026 Earnings
ARDELYX (ARDX) released its Q1 2026 earnings, reporting -$0.15 per share, missing estimates by $0.01, and revenue of $94,470,000, also falling short of estimates. Insider trading activity shows significantly more sales than purchases, while hedge funds have a mixed view with some increasing and others decreasing their positions. Analyst ratings are generally positive, with several firms issuing "Buy" or "Outperform" ratings and a median price target of $17.0.
Earnings Flash (ARDX) Ardelyx, Inc. Reports Q1 Revenue $94.5M
Ardelyx, Inc. (ARDX) reported its Q1 revenue of $94.5 million. The company is a biopharmaceutical firm focused on developing and commercializing medicines for unmet medical needs, with products like IBSRELA and XPHOZAH. Ardelyx also has pipeline programs including RDX013 for hyperkalemia and RDX020 for metabolic acidosis.
[8-K] ARDELYX, INC. Reports Material Event
Ardelyx, Inc. (ARDX) reported strong first-quarter 2026 financial results, with total product revenue jumping 38% to $93.4 million, primarily driven by IBSRELA sales. Despite strong revenue growth, the company remains loss-making with a net loss of $37.6 million, though improved from the previous year. Ardelyx reiterated its full-year 2026 revenue guidance for IBSRELA and XPHOZAH, highlighting a long-term goal of $1 billion in IBSRELA revenue by 2029 and advancements in its pipeline programs.
Ardelyx: Q1 Earnings Snapshot
Ardelyx Inc. (ARDX) reported a Q1 loss of $37.6 million, or 15 cents per share, which fell short of analyst expectations of 13 cents per share. However, the biotechnology company's revenue of $94.5 million exceeded Street forecasts of $91.5 million. Ardelyx shares have seen nearly a 9% increase year-to-date and a 15% increase over the last 12 months.
Ardelyx earnings on deck: Can IBSRELA growth offset losses?
Ardelyx is set to report its first-quarter earnings, with analysts anticipating a loss of 13 cents per share on $96.4 million in revenue. Investors will be focused on IBSRELA sales momentum and the company's path to profitability, especially in light of declining EPS and revenue estimates, and will look for updates on expense management and the Phase 3 program for IBSRELA.
ARDX Q1'26 Earnings: EPS estimate is (0.14) USD
Ardelyx, Inc. (ARDX) is slated to release its Q1'26 earnings before the market opens on April 30, with an expected disclosure time of 4:01 PM ET (8:01 PM UTC). Analysts estimate the company's revenue for the quarter to be 92.78 million USD, with an anticipated earnings per share (EPS) of (0.14) USD. The article also provides a table comparing past reported and estimated revenue and EPS figures.
[ARS] ARDELYX, INC. SEC Filing
This article announces an SEC Filing (Form ARS) by ARDELYX, INC. (ARDX) on April 29, 2026, which has a low impact and neutral sentiment. It provides details of the filing, Ardelyx's stock overview, recent news, and other SEC filings. The company's market cap, float, industry, sector, and location are also listed.
Millennium entities report 7.4% stake in Ardelyx (NASDAQ: ARDX)
Millennium Management LLC and related entities have reported a combined 7.4% stake in Ardelyx (NASDAQ: ARDX), totaling 18,043,970 shares, through a Schedule 13G/A filing. Additionally, Integrated Core Strategies (US) LLC, also associated with Millennium, reported a 7.2% stake with 17,721,732 shares. These filings indicate passive institutional holdings with shared voting and dispositive power, signed under a joint filing agreement dated April 24, 2026.
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
Ardelyx, Inc. announced that an abstract evaluating the long-term impact of its drug XPHOZAH® (tenapanor) on serum electrolytes and nutrition biomarkers has been accepted for poster presentation at the National Kidney Foundation's Spring Clinical Meetings. XPHOZAH is an FDA-approved phosphate absorption inhibitor used to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx will also sponsor a peer exchange session to discuss the drug's mechanism, efficacy, and safety.
Kidney meeting picks Ardelyx study on phosphorus drug XPHOZAH
Ardelyx announced that an abstract detailing long-term data for its drug XPHOZAH (tenapanor) has been accepted for a poster presentation at the National Kidney Foundation's Spring Clinical Meetings in May 2026. The study focuses on XPHOZAH's impact on serum electrolytes and nutrition biomarkers in dialysis patients with hyperphosphatemia, confirming it decreases serum phosphate without altering other electrolytes. Ardelyx will also sponsor a Peer Exchange at the meeting to discuss XPHOZAH's mechanism, efficacy, safety, and practical considerations as an add-on therapy.
